Investors

Press Releases

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Select Year
Search …

Found 343 Results

Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma

April 25, 2023

Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results

April 19, 2023

Pre-Clinical Data of Palatin’s Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences

April 18, 2023

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease

March 2, 2023

Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension

February 28, 2023

Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

February 15, 2023

Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023

February 10, 2023

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

January 19, 2023

Palatin Receives $4.7 Million of Non-Dilutive Funding

January 18, 2023

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

January 10, 2023

Newer

Page 9 of 35

Older